Phase I Trial of an Investigational Small Pox Medication

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
SIGA Technologies
ClinicalTrials.gov Identifier:
NCT00728689
First received: August 1, 2008
Last updated: September 15, 2010
Last verified: September 2010

August 1, 2008
September 15, 2010
August 2008
October 2008   (final data collection date for primary outcome measure)
  • Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: t½ [ Time Frame: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs ] [ Designated as safety issue: No ]
    Mean terminal half-life (t½; hrs) for Forms I and V were calculated from [plasma] vs time profiles.
  • Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: AUC0-τ [ Time Frame: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs ] [ Designated as safety issue: No ]
    Area under the drug concentration-time curve from time zero to time t, where t is the last timepoint with a drug concentration ≥ lowest obtainable quantification (AUC0-τ; ng*hr/mL).
  • Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: AUC0-∞ [ Time Frame: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs ] [ Designated as safety issue: No ]
    Area under the drug concentration-time curve from time zero to infinity (AUC0-∞; ng*hr/mL).
  • Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: Cmax [ Time Frame: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs ] [ Designated as safety issue: No ]
    Maximum drug concentration in plasma, determined directly from individual concentration-time data (Cmax)
  • Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: Tmax [ Time Frame: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs ] [ Designated as safety issue: No ]
    Time to maximum plasma concentration(Tmax; hrs) for Forms I and V were calculated from [plasma] vs time profiles.
The comparison of pharmacokinetic parameters of area under the curve (AUC) and Cmax of Form I and Form V of ST-246 400 mg (2 × 200 mg) in fed, healthy subjects as assessed through blood samples. [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00728689 on ClinicalTrials.gov Archive Site
Number of Study Participants Who Tolerated a Single Dose of ST-246 Form I vs. Form V as Determined by No Clinically Significant Changes in Safety Parameters [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

Evaluated safety parameters included:

  1. physical examination/vital signs
  2. electrocardiograms (heart rate, PR interval, QRS duration, QT interval, and QTc Bazett)
  3. laboratory safety tests (hematology, chemistry, urinalysis)
  4. adverse events For a), b) and c), summary statistics (mean,SD, median, minm, maxm)for values, and changes from baseline(Day 1 pre-dose) to each timepoint, were measured and compared to laboratory normal reference ranges. Values for a)- d) were assigned grades according to DAIDS AE Grading Table. Any Grade of 3 or higher was considered severe and significant.
To evaluate the safety and tolerability of Form I and Form V of ST-246 in fed, normal, and healthy subjects as assessed through physical examination, vital signs, electrocardiograms (ECG), laboratory tests, and adverse events (AEs). [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Phase I Trial of an Investigational Small Pox Medication
A Phase I Randomized, Double-Blind, Crossover, Exploratory Study of the Pharmacokinetics of a Single Oral Dose of Form I Versus Form V Capsules of the Anti-Orthopoxvirus Compound ST-246® in Fed Normal Healthy Volunteers

The purpose of this study was to evaluate the pharmacokinetic parameters and safety of a single dose of ST-246 400mg Form I versus ST-246 400mg Form V capsules in fed normal healthy volunteers.

This was a Phase I, double-blind, cross-over, single-dose study of the orally administered anti-orthopoxvirus compound, ST-246, to 12 healthy, fed volunteers between the ages of 18 and 50 years. Subjects were randomized such that 6 subjects received either ST-246 Form I (monohydrate) followed 10 days later after a wash-out period by Form V (hemihydrate), and 6 subjects received ST-246 Form V followed by Form I, as for the previous group.

Both forms of ST-246 were similar in the way they were manufactured. The only difference between Form I and Form V may be related to how it dissolves, and this may affect the way that it is absorbed in the human body. Information about any side-effects that may occur will also be collected in this study.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
  • Orthopoxviral Disease
  • Smallpox
  • Monkey Pox
  • Other: Days 1 - 3
    First Intervention is on Days 1 - 3, and includes 6 patients dosed once orally with ST-246 Form I (Arm 1), and 6 patients dosed once orally with ST-246 Form V (Arm 2).
    Other Name: Tecovirimat
  • Other: Days 11 - 13
    Second Intervention is on Days 11 - 13 (after a 3 day post-treatment monitoring and 7 day wash-out period) where the 6 patients previously given ST-246 Form I (Arm 1) are now dosed once orally with ST-246 Form V, and the 6 patients previously given ST-246 Form V (Arm 2) are now dosed once orally with ST-246 Form I.
    Other Name: Tecovirimat
  • Active Comparator: Group ST-246 Form I (followed by Form V)
    Each of six subjects receive a single 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat.
    Interventions:
    • Other: Days 1 - 3
    • Other: Days 11 - 13
  • Active Comparator: Group ST-246 Form V (followed by Form I)
    Each of six subjects receive a single 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat.
    Interventions:
    • Other: Days 1 - 3
    • Other: Days 11 - 13
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
12
October 2008
October 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. 18 to 50 years
  2. Available for clinical follow-up duration of study.
  3. Able/willing to give written consent.
  4. Good general health; no clinically significant medical history.
  5. Refrain from taking any medications from screening through 72 hours after last dose.
  6. Adequate venous access.
  7. PE and lab results without clinically significant findings within 28 days prior to receipt of drug.
  8. Meet Lab Criteria within 28 days prior to receipt of drug.
  9. Negative pregnancy test
  10. Non smokers
  11. No alcohol or caffeine
  12. Participant or partner has undergone surgical sterilization, or the participant agrees either to be abstinent or use two non-hormonal methods of contraception for duration of the study

Exclusion Criteria:

  1. Marked baseline prolongation of QT/corrected QT interval (QTc) interval (
  2. History of additional risk factors for Torsade de Pointes
  3. Clinically significant abnormal ECG
  4. Personal history of cardiac disease, symptomatic or asymptomatic arrhythmias, syncopal episodes, or prolongation of the PR interval
  5. Family history of Sudden Cardiac Death not clearly due to acute myocardial infarction.
  6. History of any clinically significant conditions including:

    • Asthma
    • Diabetes mellitus
    • History of thyroidectomy or thyroid disease
    • Serious angioedema episodes
    • Head trauma resulting in a diagnosis of TBI other than concussion
    • Seizure or history of seizure
    • Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with intramuscular injections or blood draws
    • Malignancy
  7. Family history of idiopathic seizures
  8. History or presence of neutropenia or other blood dyscrasia
  9. Known Hepatitis B or Hepatitis C infection
  10. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome illness.
  11. Current or recent history of a clinically significant bacterial, fungal, or mycobacterial infection.
  12. Known clinically significant chronic viral infection (or current clinically significant viral infection
  13. History of frequent or severe headaches or migraines
  14. Known chronic bacterial, mycobacterial, fungal, parasitic, or protozoal infection
  15. Woman who is pregnant or is breast-feeding or planning to become pregnant
  16. On any concomitant medications
  17. History of drug allergy that, in the opinion of the PI, contraindicates participation in the trial.
  18. Inability to swallow medication
  19. Body Mass Index above 35 or below 18,
  20. Current drug abuse or alcohol abuse.
  21. Inability to refrain from physical exercise for a period of 24 hr before and after a PK day or refrain from consuming xanthines, grapefruit or grapefruit juice
  22. Clinically significant lactose intolerance
  23. Received experimental drug within 30 days
  24. Vaccination within 30 days
  25. Total of more than 350 milliliters (mL) of blood drawn in 2 months
  26. Treatment with any immunosuppressant or immunomodulatory medication in 3 months
  27. Any condition occupational reason or other responsibility that, in the judgment of the PI, would jeopardize the safety or rights of a subject participating in the trial or would render the subject unable to comply with the protocol
  28. History or diagnosis that would affect absorption of study medication
Both
18 Years to 50 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00728689
SIGA-246-005, DMID 08-0014
Yes
Dennis Hruby, SIGA Technologies, Inc.
SIGA Technologies
National Institutes of Health (NIH)
Principal Investigator: Thomas C Marbury, MD Orlando Clinical Research Center
SIGA Technologies
September 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP